169 related articles for article (PubMed ID: 33392905)
1. Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS).
Yarosh R; Roesler MA; Murray T; Cioc A; Hirsch B; Nguyen P; Warlick E; Poynter JN
Cancer Causes Control; 2021 Mar; 32(3):241-250. PubMed ID: 33392905
[TBL] [Abstract][Full Text] [Related]
2. Chemical exposures and risk of acute myeloid leukemia and myelodysplastic syndromes in a population-based study.
Poynter JN; Richardson M; Roesler M; Blair CK; Hirsch B; Nguyen P; Cioc A; Cerhan JR; Warlick E
Int J Cancer; 2017 Jan; 140(1):23-33. PubMed ID: 27603749
[TBL] [Abstract][Full Text] [Related]
3. Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014.
Ong DM; Farrugia H; Wei A
Intern Med J; 2018 Jul; 48(7):822-829. PubMed ID: 29236346
[TBL] [Abstract][Full Text] [Related]
4. Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes.
Kuriyama K; Miyazaki Y; Arimura K; Nagai K; Nakamura H; Matsuo T; Tomonaga M
Leuk Res; 1995 Feb; 19(2):121-5. PubMed ID: 7869740
[TBL] [Abstract][Full Text] [Related]
5. Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.
Linabery AM; Roesler MA; Richardson M; Warlick ED; Nguyen PL; Cioc AM; Poynter JN
Cancer Epidemiol; 2022 Feb; 76():102090. PubMed ID: 34995873
[TBL] [Abstract][Full Text] [Related]
6. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.
Kristinsson SY; Björkholm M; Hultcrantz M; Derolf ÅR; Landgren O; Goldin LR
J Clin Oncol; 2011 Jul; 29(21):2897-903. PubMed ID: 21690473
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for myelodysplastic syndromes: a case-control study in Greece.
Dalamaga M; Petridou E; Cook FE; Trichopoulos D
Cancer Causes Control; 2002 Sep; 13(7):603-8. PubMed ID: 12296507
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
9. Occupational, dietary, and other risk factors for myelodysplastic syndromes in Western Greece.
Avgerinou C; Giannezi I; Theodoropoulou S; Lazaris V; Kolliopoulou G; Zikos P; Alamanos Y; Leotsinidis M; Symeonidis A
Hematology; 2017 Aug; 22(7):419-429. PubMed ID: 28102107
[TBL] [Abstract][Full Text] [Related]
10. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database.
Wilson AB; Neogi T; Prout M; Jick S
Cancer Epidemiol; 2014 Oct; 38(5):544-9. PubMed ID: 25189344
[TBL] [Abstract][Full Text] [Related]
11. Environmental and occupational determinants of myelodysplastic syndrome: A case-control study from Pakistan.
Anwar N; Arshad A; Fatima N; Shaheen S; Bukhari S; Shamsi T
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1580. PubMed ID: 34708590
[TBL] [Abstract][Full Text] [Related]
12. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
13. Risk factors of myelodysplastic syndromes: a case-control study.
Strom SS; Gu Y; Gruschkus SK; Pierce SA; Estey EH
Leukemia; 2005 Nov; 19(11):1912-8. PubMed ID: 16167059
[TBL] [Abstract][Full Text] [Related]
14. De-novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) and myelodysplastic remission marrow (AML/MRM).
Tamura S; Kanamaru A
Leuk Lymphoma; 1995 Jan; 16(3-4):263-70. PubMed ID: 7719234
[TBL] [Abstract][Full Text] [Related]
15. Alcohol use is not a significant contributor to myelodysplastic syndromes.
Duffy EA; Nguyen PL; Cioc A; Warlick E; Roesler MA; Poynter JN
Cancer Causes Control; 2020 Jun; 31(6):549-557. PubMed ID: 32285234
[TBL] [Abstract][Full Text] [Related]
16. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Ertz-Archambault N; Kosiorek H; Taylor GE; Kelemen K; Dueck A; Castro J; Marino R; Gauthier S; Finn L; Sproat LZ; Palmer J; Mesa RA; Al-Kali A; Foran J; Tibes R
JAMA Oncol; 2017 Jul; 3(7):936-943. PubMed ID: 28152123
[TBL] [Abstract][Full Text] [Related]
17. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.
Merlat A; Lai JL; Sterkers Y; Demory JL; Bauters F; Preudhomme C; Fenaux P
Leukemia; 1999 Feb; 13(2):250-7. PubMed ID: 10025899
[TBL] [Abstract][Full Text] [Related]
18. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
19. Tea consumption reduces the risk of de novo myelodysplastic syndromes.
Liu P; Zhang M; Jin J; Holman CD
Leuk Res; 2015 Feb; 39(2):164-9. PubMed ID: 25529769
[TBL] [Abstract][Full Text] [Related]
20. The association between non-steroidal anti-inflammatory drugs (NSAIDs) and myelodysplastic syndromes in the Adults in Minnesota with Myelodysplastic Syndromes (AIMMS) Study.
Hubbard AK; Richardson M; Rosesler MA; Cioc A; Nguyen PL; Warlick E; Poynter JN
Leuk Lymphoma; 2021 Jun; 62(6):1474-1481. PubMed ID: 33416407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
